Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: H2L5186303 is a selective lysophosphatidic acid 2 (LPA2) receptor antagonist (IC50 = 9 nM in a LPA-elicited calcium mobilization assay). It inhibits LPA1 and LPA3 at much higher concentrations (IC50s = 27,354 and 4,504 nM, respectively).
H2L5186303 is supplied as a crystalline solid. A stock solution may be made by dissolving the H2L5186303 in the solvent of choice. H2L5186303 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of H2L5186303 in these solvents is approximately 15 and 20 mg/ml, respectively. H2L5186303 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, H2L5186303 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. H2L5186303 has a solubility of approximately 0.11 mg/ml in a 1:8 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Fells, J. I., Tsukahara, R., Liu, J., et al. Structure-based drug design identifies novel LPA3 antagonists. Bioorg. Med. Chem. 17(21), 7457-7464 (2009).